Podcasts about nonalcoholic fatty liver disease

Do you feel you've been on every diet under the sun, yet without any lasting results to show for it? Somehow, the weight loss never seems to stick and you end up gaining all of it back, and then some. That was my guest Lyana's experience and it felt incredibly frustrating. Not only that, her health seemed to be headed in the wrong direction too, and it was a shock for her to receive new diagnoses like diabetes and Nonalcoholic Fatty Liver Disease.   But instead of doing keto, she decided to re-try a plant-based diet, and went full into a whole food, plant-based diet with no oil. Listen in to Part 2 of my interview with Lyana to hear more about her amazing health transformation, and the positive health benefits her husband has also enjoyed. Don't miss too the important key takeaway piece of advice Lyana gives us about losing weight on a plant-based diet!     Contact -> healthnow@plantnourished.com Learn -> www.plantnourished.com Join -> www.plantnourished.com/ppltcourse Connect in the Facebook Community -> www.bit.ly/pbdietsuccess Apply -> Free Rapid Health Transformation Call: https://bit.ly/plantnourished Free Resource -> Quick Start Grocery Guide for Plant-Based Essentials: www.plantnourished.com/groceryguide     Have a question about plant-based diets that you would like answered on the Plant Based Eating Made Easy Podcast? Send it by email (healthnow@plantnourished.com) or submit it by a voice message here: www.speakpipe.com/plantnourished [Plant-Based Diet, Plantbased Eating, Plant Based Diet, Whole Foods, NAFLD, Blood Sugars, Glucose Control, Weight Loss, Pain, Inflammation, Hypertension, High Cholesterol, Pre-Diabetes]

My interview guest Lyana S. never wanted to go on prescription meds. Yet, health issues started piling up, one after another, from her late thirties onwards. First it was high blood pressure, then high cholesterol and pre-diabetes. Then finally diabetes and Nonalcoholic Fatty Liver Disease. Add to this a strong family history of medical issues, with her mother suffering from diabetes, kidney failure, then a severe stroke and paralysis. It's clear the odds aren't stacked in her favor.   Lyana knew things need to change, but how? That's when she began a whole food, no-oil, plant-based diet, and her health changed dramatically within the next few months. Listen in to Part 1 of my interview with Lyana and be inspired by her fascinating story!     Contact -> healthnow@plantnourished.com Learn -> www.plantnourished.com Join -> www.plantnourished.com/ppltcourse Connect in the Facebook Community -> www.bit.ly/pbdietsuccess Apply -> Free Rapid Health Transformation Call: https://bit.ly/plantnourished Free Resource -> Quick Start Grocery Guide for Plant-Based Essentials: www.plantnourished.com/groceryguide     Have a question about plant-based diets that you would like answered on the Plant Based Eating Made Easy Podcast? Send it by email (healthnow@plantnourished.com) or submit it by a voice message here: www.speakpipe.com/plantnourished [Plantbased Eating, Plant Based Diet, Whole Foods, NAFLD, Blood Sugars, Glucose Control, Weight Loss, Pain, Inflammation, Hypertension, High Cholesterol, Pre-Diabetes]

In this week's episode, we discuss Metabolic Dysfunction Associated Steatotic Liver Disease (formerly known as Non-Alcoholic Fatty Liver Disease or NAFLD): what it is, how you get it, and most importantly, how to treat it. This week's recipe is Strawberry Lemon Sorbet. Schedule a visit today at www.bodymetrixhealth.com.

Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002045. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/37700494/ Fibrosis-4 (FIB-4) Calculator https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 Liver Fibrosis Assessment: MR and US Elastography https://pubmed.ncbi.nlm.nih.gov/34687329/ Using the FIB-4, Automatically Calculated, Followed by the ELF Test in Second Line to Screen Primary Care Patients for Liver Disease https://pubmed.ncbi.nlm.nih.gov/38806580/ American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) https://pubmed.ncbi.nlm.nih.gov/35569886/ Mediterranean Diet and Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/29785077/ Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction https://pubmed.ncbi.nlm.nih.gov/39470028/ Current Status of Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/39801787/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Update on the Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/35110946/

In this episode I look at the liver and how to keep it healthy, arguably the most industrious visceral organ in our body with so many critical functions. Non-Alcoholic Fatty Liver Disease: https://www.hopkinsmedicine.org/health/conditions-and-diseases/nonalcoholic-fatty-liver-diseaseFructose: https://www.nih.gov/news-events/nih-research-matters/how-high-fructose-intake-may-trigger-fatty-liver-diseaseGlycogen: https://my.clevelandclinic.org/health/articles/23509-glycogenUltra processed food and liver disease: https://pubmed.ncbi.nlm.nih.gov/37871746/Alcohol and liver disease: https://www.hopkinsmedicine.org/health/conditions-and-diseases/alcoholinduced-liver-diseaseWIlson's Disease: https://www.mayoclinic.org/diseases-conditions/wilsons-disease/symptoms-causes/syc-20353251Haemochromatosis: https://www.haemochromatosis.org.uk/Jaundice: https://www.nhs.uk/conditions/jaundice/Gall bladder removal - cholecsytecomy: https://my.clevelandclinic.org/health/procedures/21614-gallbladder-removalDiarrhoea after gall bladder removal: https://pmc.ncbi.nlm.nih.gov/articles/PMC10725554/Hepatitis 'alphabet': https://www.who.int/news-room/questions-and-answers/item/hepatitisGallbladder diet: https://www.healthline.com/health/gallbladder-dietMetabolic pathways in detoxification: https://onlinelibrary.wiley.com/doi/10.1155/2015/760689Coffee and other foods: https://www.medicalnewstoday.com/articles/323915 Hosted on Acast. See acast.com/privacy for more information.

Nutrition Nugget! Bite-size, bonus episodes offering tips, tricks and approachable science. This week, Jenn is talking about Non-Alcoholic Fatty Liver Disease. Your liver health could be at risk without you even realizing it. Non-alcoholic fatty liver disease (now called MASLD for metabolic dysfunction-associated steatotic liver disease)—is a silent yet widespread condition impacting 25+% of Americans. Discover how simple lifestyle changes can help reverse liver fat buildup, the surprising link between sugar and liver health, and why your morning coffee timing matters more than you think! Also, learn which everyday foods to avoid and the powerhouse nutrients supporting a healthy liver. This is the information your liver has been waiting for! Like what you're hearing? Be sure to check out the full-length episodes and new releases every Wednesday.  Have an idea for a nutrition nugget?  Submit it here: https://asaladwithasideoffries.com/index.php/contact/       RESOURCES:Become A Member of Salad with a Side of FriesJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramThe Truth About Alcohol/Salad With a Side of Fries - PodcastOmega 3 Curcumin and Liver Support. Supplements

Welcome to The Veterans Disability Nexus, where we provide unique insights and expertise on medical evidence related to VA-rated disabilities.Leah Bucholz, a US Army Veteran, Physician Assistant, & former Compensation & Pension Examiner shares her knowledge related to Independent Medical Opinions often referred to as “Nexus Letters” in support of your pursuit of VA Disability every Wednesday at 7 AM.In this video Leah addresses the issue of non-alcoholic fatty liver disease (NAFLD) and its connection to obesity in the context of VA disability. She explains that NAFLD is a common liver condition affecting individuals who consume minimal to no alcohol, primarily seen in those who are overweight or obese. This condition, which affects about 25% of the global population and 100 million people in the U.S., can progress to non-alcoholic steatohepatitis (NASH), leading to severe liver damage similar to that caused by heavy alcohol use. Leah highlights the importance of recognizing obesity as a contributing factor to NAFLD and discusses various studies on the relationship between obesity, physical inactivity, and NAFLD. She emphasizes the role of weight loss and physical activity in managing NAFLD, referencing guidelines that recommend these as primary treatments. Additionally, she outlines the VA disability ratings for conditions related to NAFLD, stressing the need for a current diagnosis, an in-service event, injury, or illness, and a link between the service event and the current disability.

In today's podcast, you will learn about the growing epidemic of fatty liver disease and its impact on global health. You will gain insights into the causes, risk factors, and critical differences between non-alcoholic and alcoholic fatty liver disease. Understanding the range of symptoms and potential complications associated with fatty liver disease allows you to recognize warning signs early, which is a crucial step in managing your health. You will also learn about lifestyle modifications, treatment options, and future developments in controlling and preventing fatty liver disease, enabling you to take proactive steps toward liver health.

In this episode, Tess talks with Kristin Kirkpatrick - renowned speaker, best-selling author, and one of the most respected dietitians in the United States. Kristin shares how her struggle with childhood obesity fueled her desire to help people improve their relationship with food. Then traces her journey from White House intern, to lobbyist, to cardiovascular genetics at the Cleveland Clinic, to lead dietitian of their Department of Integrative and Lifestyle Medicine. She speaks to the value of humility and generous mentorship in finding your own path and helping others find theirs. And how stepping out of your comfort zone fast-tracks personal and professional growth. Kristin's talent for simplifying complex medical information has made her a powerful force in nutrition education. She explains why we need to care about the liver, and why Non-Alcoholic Fatty Liver Disease has become an epidemic. With an estimated 1 in 4 people affected, and many unaware they have it, the disease is a silent killer. She defines the four metabolic types, why knowing your type is critical, and gives practical strategies for preventing and reversing liver disease. In closing, she shares her next mission: Helping women embrace menopause with humor and love their older bodies! KEY MOMENTS IN THE PODCAST “You can go through so many different versions of yourself. Eventually you're gonna land on who you're meant to be. And sometimes you gotta go through all those versions to figure it out.” “A lot of times we'll take on different things in our life because we didn't have it. So we take that on as a goal to give back what was not given to us.” “When the view doesn't change, you can't necessarily grow. It's the stuff that makes you uncomfortable where you're forced to learn about something you didn't know before.” “1 out of every 4 people has liver disease and probably don't know it because there's no symptoms. We think it's closer to 30% of individuals who have it. It's very much in line with type-two diabetes and insulin resistance. It is an epidemic and a silent killer.” KRISTIN KICKPATRICK, MS, RDN BIO With over 25 years experience in health management, Kristin is an award-winning dietitian, best-selling author, nationally recognized speaker, and founder and president of KAK Consulting, LLC,. As the lead dietitian in the Cleveland Clinic's Department of Integrative and Lifestyle Medicine, Kristin is one of the most respected dietitians in the United States. You may have seen her give expert advice on the TODAY show, NBC Nightly News, the Dr. Oz show, as well as the New York Times, Wall Street Journal, TIME, Oprah, Food Network, Self, Women's Health, and other media outlets. Kristin is known for her groundbreaking lobbying efforts for Medical Nutrition Therapy reform on behalf of the American Dietetic Association Policy and Advocacy group. Kristin's first book, Skinny Liver got a lot of attention raising awareness about the Non-Alcoholic Fatty Liver Disease epidemic. Her second book, Regenerative Health explores the relationship between liver disease and metabolic health, and provides practical nutrition plans and strategies to support recovery and better health. CONNECT WITH KRISTIN Website: https://www.kristinkirkpatrick.com/ Nutrogenomic Testing: https://www.kristinkirkpatrick.com/nutrogenomic-testing Facebook: https://www.facebook.com/fuelwellwithkrissy Instagram: https://www.instagram.com/fuelwellwithkrissy/ LinkedIn: https://www.linkedin.com/in/kristinkirkpatrickrd/ CONNECT WITH TESS Website: https://tessmasters.com/ Podcast Website: https://ithastobeme.com/  Facebook: https://www.facebook.com/theblendergirl/ Instagram: https://www.instagram.com/theblendergirl/ Twitter: https://twitter.com/theblendergirl YouTube: https://www.youtube.com/user/theblendergirl LinkedIn: https://www.linkedin.com/in/tessmasters/ Product Sites: https://www.skinny60.com/ https://www.thedecadentdetox.com/ https://www.theblendergirl.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Nonalcoholic fatty liver disease (NAFLD) is prevalent in 25–30% of British and European populations, representing a potential global public health crisis. Marine omega-3 (n-3) polyunsaturated fatty acids offer well-evidenced benefits to NAFLD biomarkers; however, the effect of plant-based n-3 has not been evaluated with a systematic review and meta-analysis. Join us for this episode where Douglas Taren speaks with Katie Lane, co-author of this featured article, a review aimed to systematically evaluate the effect of plant-based n-3 supplementation on NAFLD surrogate biomarkers and parameters.

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

Episode 12 - New Study on Treatments for Non-Alcoholic Fatty Liver Disease in People With HIV With Dr Jordan Lake Recorded Live from CROI 2024In this episode, Dr Michael Saag speaks with Dr Jordan Lake live from the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). They discuss the prevalence of non-alcoholic fatty liver disease (NAFLD) among people with HIV and explore the effectiveness of the GLP-1 receptor agonist semaglutide, commonly used to treat diabetes and aid in weight loss, to treat NAFLD. Future areas of research are considered, including maintenance strategies post-weight loss and a placebo-controlled version of the study.00:02 Introduction and Welcome00:44 Discussion on Non-Alcoholic Fatty Liver Disease in People With HIV01:56 Role of HIV in Non-Alcoholic Fatty Liver Disease02:43 Understanding the Inflammation and Fat Accumulation in the Liver04:38 Exploring the Impact of Nucleoside Therapy on Non-Alcoholic Fatty Liver Disease06:37 Potential Treatments for Non-Alcoholic Fatty Liver Disease07:35 The Role of Semaglutide in Treating Non-Alcoholic Fatty Liver Disease13:36 The Importance of Routine Assessment for Non-Alcoholic Fatty Liver Disease15:37 Exploring New Drugs for Treating Non-Alcoholic Fatty Liver Disease18:49 The Challenges and Future Directions in Non-Alcoholic Fatty Liver Disease Research22:25 Conclusion and Closing Remarks__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTube InstagramTikTok...

Zobair Younossi, Chair of the Global NASL Council, publishes seminal papers  on MASLD epidemology, cost of disease, and related public health needs regularly. Co-hosts Jörn Schattenberg, Louise Campbell, and Roger Green ask questions and share perspectives from their own experiences.00:00:00 - Surf's Up: Season 5 Episode 4Opening introduction, including brief quotes taken directly from the episode discussion.00:02:45 - Introduction and GroundbreakerPanelists swap brief, lighthearted comments about where they are geographically and where they have been recently. In the groundbreaker, each shares one piece of good news from the previous week. 00:11:15 - Epidemiology articleZobair Younossi discusses the recent review article, Understanding the Burden of Nonalcoholic Fatty Liver Disease, published earlier this month in Diabetes Spectrum. He starts by discussing incidence and growth rates for MASLD, MASH, and cirrhosis across the world, and how these differ by country. He goes on to discuss the impact of MASH on patient Quality of Life and the high correlation between multi-metabolic patients (most notably diabetics) and negative outcomes.00:15:55 - Panel questions and commentsJörn Schattenberg joins the conversation to praise this and other of Zobair's works for helping physicians know what to do when they decide to become more engaged in treating MASLD and MASH. This leads Zobair to discuss the Markov model they have created to evaluate burden of disease.00:19:14 - Costliness and cost-effectiveness of therapy In response to a question from Roger Green, Zobair describes the criteria and metrics used to evaluate the cost-effectiveness of a new drug or diagnostic. Louise Campbell comments on how high and underappreciated the social and economic burdens of disease are to every global society. Zobair notes that health economists do not focus on liver disease as a discreet set of costs and burdens. 00:27:17 - Goals and activities for the next few yearsRoger states that given how fast the  MASLD and MASH populations are growing, an effort to "flatten the curve" would be heroic. Zobair replies that each country needs to fight liver disease, but that each country will have different immediate challenges. 00:31:28 - Women's health and liver healthLouise notes that the epidemiology paper refers to the high level of risks among women over 55. This leads to a discussion between Jörn, Zobair and Louise on the higher risk level post-menopausal women experience and some pathological elements that make this important.00:34:58 - Global NASH CouncilZobair bridges this portion of the conversation to discuss the work of the Global NASH Council, a group of >200 members in >50 countries organized into different workstreams to create knowledge and awareness around MASLD and MASH.00:38:59 - Low SDI and High SDI countriesTo Zobair, one element in the global effort on MASLD and MASH is the recognition that High SDI (wealthier) and Low SDI (power) countries face dramatic differences in the challenges they face. 00:41:14 - Reducing the rate of disease growthTo Louise, educating women might be a key to driving awareness, both because post-menopausal women live at higher risks and because they cook and schedule for their families. This leads to a broader discussion about the most effective education starting with children. Finally, Zobair discusses the importance of making all stakeholders PLUS global agencies recognize the scale of this challenge and to act in concert with increasing urgency. 00:48:42 - Question of the WeekThe first Question of the Week asks what steps each of us can take to help stem the pandemic. 00:49:41 - Business reportNews on audience metrics, the first Question of the Week, next week's episode and this week's Vault conversation

Today, you'll learn about how your next scrape might be healed using algae, what ancient Mayans can teach us about water conservation, and the skincare routines… of humpback whales Healing Algae “Plasma tech transforms blue-green algae into wound-healing wonder.” by Paul McClure. 2023. “Health Benefits of Blue-Green Algae: Prevention of Cardiovascular Disease and Nonalcoholic Fatty Liver Disease.” by Chai Siah Ku, et al. 2013. “Transforming Spirulina maxima Biomass into Ultrathin Bioactive Coatings Using an Atmospheric Plasma Jet: A New Approach to Healing of Infected Wounds.” by Tuyet Pham, et al. 2023. Mayan Reservoirs Ancient Maya reservoirs, constructed wetlands, and future water needs.” by Lisa J. Lucero. 2023. “Who were the Maya? Decoding the ancient civilization's secrets.” by Erin Blakemore. 2022. Humpback Skincare “What's at Play: Humpback Whale Interaction with Seaweed Is a Global Phenomenon.” by Jan-Olaf Meynecke & Hilla Kela. 2023. “Kelping is a ‘global phenomenon' sweeping the world of humpback whales, scientists say.” by Sascha Pare. 2023. “Humpback whales: Facts about the singers of the sea.” by Patrick Pester. 2023. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

Most of us have heard of fatty liver being associated with alcoholism or consumption of large quantities of alcohol.  But this isn't the only cause of fatty liver.  The vast majority of fatty liver cases today are not related to alcohol consumption, but rather due to metabolic changes in the liver (and throughout the body).  This is referred to as Non-Alcoholic Fatty Liver Disease or Metabolic Associated Fatty Liver Disease.Fatty liver is not the result of obesity and isn't found only in those who are obese.  NAFLD is associated with insulin resistance.  Listen to this episode to learn more about how you can reverse fatty liver quickly without medications.  For full show notes and information, click here.Did you know my practice is entirely virtual? You don't have to live near me to get help with fatigue, stubborn weight, hypertension, prediabetes or more?Schedule a free call Free Metabolic Mastery ManualFree Facebook Community

Today, we examine the impact of ultra-processed foods on liver health. This shift in our diet has had an impact on our liver health, resulting in the important organ not functioning properly, for us and our kids. Dr. Elizabeth Boham presents a case-study of a patient she had who had developed non-alcoholic fatty liver disease and what she did to help him. Many of us turn to cleanses to detox our livers, but what if we instead reduced our reliance on ultra-processed foods instead?   LET'S TALK THE WALK! ***NEW*** Facebook Group for Our Community! Join here for support, motivation and fun! Wellness While Walking Facebook page Wellness While Walking on Instagram Wellness While Walking on Twitter Wellness While Walking website for show notes and other information wellnesswhilewalking@gmail.com Wellness While Walking on Threads     RESOURCES AND SOURCES (some links may be affiliate links) FATTY LIVER DISEASE (NAFLD/MDASLD) AND ULTRA-PROCESSED FOODS Fatty Liver Was a Disease of the Old. Then Kids Started Getting Sick, washingtonpost.com Metabolic Dysfunction-Associated Steatotic Liver Disease, my.clevelandclinic.org Ultra-Processed Food Intake is Associated with Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review and Meta-Analysis, ncbi.nlm.nih.gov Non-Alcoholic Fatty Liver Disease, my.clevelandclinic.org The Nova Food Classification System, ecuphysicians.ecu.edu Consumption of Ultraprocessed Foods and Risk of Multimorbility of Cancer and Cardiometabolic Diseases, thelancet.com Some Ultra-Processded Foods Are Good for Your Health, WHO-Backed Study Finds, theguardian.com Eating Ultra-Processed Foods Puts Your Liver At Risk, New Study Warns, news-medical.net Avoid This Diet to Prevent FATTY LIVER DISEASE - Mark Hyman, MD, youtube.com   HOW TO SHARE WELLNESS WHILE WALKING Tell a friend or family member about Wellness While Walking, maybe while you're walking together or lamenting not feeling 100% Follow up with a quick text with more info, as noted below! (My favorite is pod.link/walking because it works with all the apps!) Screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Wellness While Walking on Apple – click the up arrow to share with a friend via text or email, or share to social media Wellness While Walking on Spotify -- click the up arrow to share with a friend via text or email, or share to social media Use this universal link for any podcast app: pod.link/walking – give it to friends or share on social media Tell your pal about the Wellness While Walking website Thanks for listening and now for sharing! : )       DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking.     Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!

Dangerous misrepresentations of the health of our food abound on social media. Who's behind this and how can we protect our health in the face of this disingenuous communication?    LET'S TALK THE WALK! ***NEW*** Facebook Group for Our Community! Join here for support, motivation and fun! Wellness While Walking Facebook page Wellness While Walking on Instagram Wellness While Walking on Twitter Wellness While Walking website for show notes and other information wellnesswhilewalking@gmail.com Wellness While Walking on Threads     RESOURCES AND SOURCES (some links may be affiliate links) The Food Industry Pays “Influencer” Dieticians to Shape Your Eating Habits, washingtonpost.com Ultra-Processed Food Consumption and the Risk of Non-Alcoholic Fatty Liver Disease, academic.oup.com HOW TO SHARE WELLNESS WHILE WALKING Tell a friend or family member about Wellness While Walking, maybe while you're walking together or lamenting not feeling 100% Follow up with a quick text with more info, as noted below! (My favorite is pod.link/walking because it works with all the apps!) Screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Wellness While Walking on Apple – click the up arrow to share with a friend via text or email, or share to social media Wellness While Walking on Spotify -- click the up arrow to share with a friend via text or email, or share to social media Use this universal link for any podcast app: pod.link/walking – give it to friends or share on social media Tell your pal about the Wellness While Walking website Thanks for listening and now for sharing! : )       DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking.     Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!          

Episode #281. With nearly a quarter of the world's population estimated to be affected by non-alcoholic fatty liver disease (NAFLD), understanding its intricacies is crucial. Join me as Dr Alan Flanagan helps unravel the complexities of NAFLD, breaks down its wider health ramifications, and offers insights on managing and living with the condition. We discuss: Introduction to Fatty Liver Disease (00:00) Understanding Non-Alcoholic Fatty Liver Disease and Its Development (02:27) Risk Factors: Gender Differences in Fatty Liver Disease Development (09:33) The Science of Hepatic Fat Oxidation (14:45) Consequences and Effects of Fatty Liver Disease (20:25) Identifying Symptoms of Non-Alcoholic Fatty Liver Disease (25:54) Risk Assessment: Non-Alcoholic Fatty Liver Disease in Premenopausal Women (29:33) Energy Toxicity and Misconceptions about BMI (34:50) Linking Non-Alcoholic Fatty Liver Disease with Type 2 Diabetes (48:34) Liver Changes During Non-Alcoholic Fatty Liver Disease Progression (1:02:16) Strategies for Reducing Fat Accumulation in the Liver (1:05:28) The Role of Time-Restricted Eating in Managing Fatty Liver Disease (1:11:41) The Impact of Sugars on Fatty Liver Disease (1:20:16) Understanding the Relationship Between Dietary Fats and Fatty Liver Disease (1:41:16) High Saturated Fat Diets and Their Effect on Fatty Liver Disease (1:57:19) Importance of Caloric Source Variation in Dietary Fats (1:59:23) Beneficial Dietary Patterns for Liver Health (2:04:07) Analysing Dairy Types and Their Effects on Liver Fat (2:08:29) Meal Frequency and Its Relation to Liver Fat Accumulation (2:12:40) Recommended Lifestyle Changes for Preventing Non-Alcoholic Fatty Liver Disease (2:17:59) Conclusion: Key Takeaways on Fatty Liver Disease Management (2:20:07) Connect with Alan Flanagan on Instagram, and learn more about his company, Alinea Nutrition, here. Make sure to listen to his five previous appearances on The Proof here. Optimise your health with InsideTracker's biomarker analysis. Get exclusive access to InsideTracker's new ApoB test, and a significant discount at insidetracker.com/simon. Enjoy, friends. Simon Want to support the show? The best way to support the show is to use the products and services offered by our sponsors. To check them out, and enjoy great savings, visit theproof.com/friends. You can also show your support by leaving a review on the Apple Podcast app and/or sharing your favourite episodes with your friends and family. Simon Hill, MSc, BSc (Hons) Creator of theproof.com and host of The Proof with Simon Hill Author of The Proof is in the Plants Watch the episodes on YouTube or listen on Apple/Spotify Connect with me on Instagram, Twitter, and Facebook Nourish your gut with my Plant-Based Ferments Guide Download my complimentary Two-Week Meal Plan and high protein Plant Performance recipe book

In this Re Release of Episode 10 on 5/10/23 of the School of Doza podcast, Nurse Doza discusses how to lose weight when you are insulin resistant. He starts by emphasizing the commitment needed to make these changes and encourages listeners to sign up for the newsletter on Nursedoza.com for weekly content and advice. Nurse Doza then explains that insulin resistance is common and leads to inflammation, and provides specific changes that can help with weight loss.   TIMESTAMPS: 00:00 Start 02:25 Insulin resistance and weight gain. 04:21  Insulin Resistance and Diabetes. 08:02 Leptin Resistance and Weight Loss. 11:50 Brown fat and weight loss. 19:42 Insulin resistance and weight loss. 24:29 Activation of parasympathetic nervous system. 27:23 Insulin Resistance and Weight Loss. 31:57 Resveratrol supplement.     Increase your energy levels and support your metabolism with Mitochondriac! Get 10% off when you use code NURSEDOZA at checkout. Visit the link to learn more and start feeling your best today! https://www.mswnutrition.com/mitochondriac         REFERENCES: What being insulin resistant means: _inflammation   your body is reluctant to release anymore insulin___ (1) “Insulin resistance is identified as an impaired biologic response to insulin stimulation of target tissues, primarily the liver, muscle, and adipose tissue” (2)   “You do not have to be overweight to have insulin resistance” (1)    “The spectrum of disease associated with insulin resistance includes obesity, cardiovascular disease, nonalcoholic fatty liver disease, metabolic syndrome, and polycystic ovary syndrome(PCOS).” (2)    Ways to measure IR: “HOMA-IR, serum triglyceride, and triglyceride/HDL ratio.” (2)   **“Insulin resistance is thought to precede the development of T2DM by 10 to 15 years. “ (2)   “While no medications are FDA approved for the treatment of insulin resistance” (3)  “Lifestyle modification should be the primary focus for the treatment of insulin resistance.” (3)   References: https://www.cdc.gov/diabetes/basics/insulin-resistance.html (1)  https://www.ncbi.nlm.nih.gov/books/NBK507839/ (2) IR: https://www.ncbi.nlm.nih.gov/books/NBK507839/ (3)    Leptin: “Leptin resistance is defined by a reduced sensitivity or a failure in response of the brain to leptin, showing a decrease in the ability of leptin to suppress appetite or enhance energy expenditure, which causes an increased food intake and finally leads to overweight, obesity, cardiovascular diseases, and other metabolic disorders” (1)   “A minor increase in leptin concentration reduces the appetite and leads to a decrease in body weight;3 however, in obesity, despite increased leptin concentration, the efficacy of the anorexic effect of leptin is decreased,1,3 with leptin resistance developing due to a defect in intracellular signaling associated with the leptin receptor or decreases in leptin transport across the blood–brain barrier (BBB)” (2)   “participation of leptin in the development of cardiovascular and autoimmune diseases and cancer” (2)  References: leptin: https://pubmed.ncbi.nlm.nih.gov/30390289/ (1) Leptin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354688/ (2) IR: https://www.ncbi.nlm.nih.gov/books/NBK507839/ (3)   References: leptin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354688/ (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815269/ (2)  https://academic.oup.com/jcem/article/91/12/4753/2656230?login=false (3)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848049/ (4)   References: https://www.diabetes.co.uk/insulin/insulin-sensitivity.html (1) https://www.ncbi.nlm.nih.gov/books/NBK507839/ (2)  Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action https://pubmed.ncbi.nlm.nih.gov/28704113/ (3)  Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371579/ (4) https://academic.oup.com/jcem/article/91/12/4753/2656230?login=false (5)   References: The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease https://academic.oup.com/jcem/article/91/12/4753/2656230?login=false (1) https://www.pnas.org/doi/10.1073/pnas.2007856117 (2)    “In people with diabetes and pre-diabetes, increasing levels of HbA1c and age may be main factors related to impaired parasympathetic function” (1)   “Depression has been associated with both increased insulin resistance and reduced heart rate variability (HRV), the latter being an indicator of low parasympathetic drive” (2)   References: https://www.nature.com/articles/s41598-022-22675-2 (1)  https://www.researchgate.net/publication/47383873_Lower_Parasympathetic_Drive_Insulin_Resistance_and_Depression (2)   

Questions & cases regarding diagnostic workup and management for PBC, PSC, Alcoholic & Non-Alcoholic Fatty Liver Disease (steatosis, steatohepatitis), and Vascular Hepatopathy

In this episode, Nurse Doza addresses the common issue of weight loss plateaus and offers advice on what to do when facing this challenge. He shares his personal experience and success stories, emphasizing the importance of the liver in weight loss.    TIMESTAMPS: 00:00 START 02:12 Elimination diet and weight loss. 05:47 Sensitivity to tomatoes and weight loss. 06:09 Weight loss and diet struggles. 08:40 Fasting and weight loss. 13:31 Kickstarting after a weight loss plateau. 16:39 Cold exposure and fat cells. 18:18 Making more brown fat. 21:02 Liver detox and weight loss. 24:07 Weight loss and health.   Before we dive into the SHOW NOTES, we want to spotlight an essential health ally – the liver. A well-functioning liver is vital for efficient fat metabolism and overall wellness. Understanding this, MSW has developed a specialized supplement, Liver Love. Liver Love is designed to detoxify, cleanse, and support your liver, significantly contributing to your weight loss efforts. If your weight loss progress has stalled, taking care of your liver health might be the key to breaking through that plateau. Ready to show your liver some love? Visit idovitamins.com/liverlove and use the code NURSEDOZA at checkout to get a special discount. Incorporate Liver Love into your daily routine and empower your body to achieve effective and sustainable weight loss. Trust us; your liver will thank you.     SHOW NOTES 1. **Elimination diet: The first way to kickstart your weight loss again** Elimination diets are considered the gold standard for identifying foods that may not agree with your body^1. Common food allergens include eggs, fish, milk, peanuts, shellfish, soy, tree nuts, and wheat^1. Other problematic substances can include alcohol, corn, histamines, gluten, fructose, lactose, nitrites, MSG, and nightshades^1. [Study: Elimination Diet](https://health.clevelandclinic.org/elimination-diet/) ^1 2. **Fasting: The second way to kickstart your weight loss again** Insulin resistance (IR) contributes to a variety of health issues, including atherosclerosis, type 2 diabetes, hypertension, cardiovascular disease, and various cancers^2. Current research suggests that intermittent fasting is a viable non-medical treatment option for type 2 diabetes^3. Fasting can also normalize certain physiological parameters in obese individuals^2. [Study 1: Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448479/) ^2 [Study 2: Prolonged fasting-induced metabolic signatures in human skeletal muscle of lean and obese men](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124727/) ^2 [Study 3: Intermittent fasting: is there a role in the treatment of diabetes? A review of the literature and guide for primary care physicians](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856758/) ^3 3. **Sunlight: The third way to kickstart your weight loss again** Exposure to blue light can potentially impact lipid homeostasis^4. In another study, exposure to morning light was associated with reduced body fat and appetite in obese women^5. [Study 1: Subcutaneous white adipocytes express a light sensitive signaling pathway mediated via a melanopsin/TRPC channel axis](https://www.nature.com/articles/s41598-017-16689-4) ^4 [Study 2: Timing and Intensity of Light Correlate with Body Weight in Adults](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973603/) ^5 4. **Cold exposure: The fourth way to kickstart your weight loss again** Cold exposure can stimulate BAT activity, increase glucose and lipid uptake, and lead to metabolic benefits like increased energy expenditure and insulin sensitivity^6. [Study: Cold and Exercise: Therapeutic Tools to Activate Brown Adipose Tissue and Combat Obesity](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466122/) ^6 5. **Detoxing the liver: The fifth way to kickstart your weight loss again** [Study: The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease](https://academic.oup.com/jcem/article/91/12/4753/2656230) ^7   Use supplement code NURSEDOZA at idovitamins.com . Always remember how much power you have in your hands! I've seen many people turn things around; there is no doubt in my mind that you can do it too.  

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That's why Dr. Peter Buch speaks with Dr. Sidney Barritt about even more treatment strategies for nonalcoholic fatty liver disease in the second and final part of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Sidney Barritt, MD Even though nonalcoholic fatty liver disease is the most common form of chronic liver disease in the United States, there are unfortunately no FDA-approved medications for this condition. That's why Dr. Peter Buch speaks with Dr. Sidney Barritt about top treatment strategies for nonalcoholic fatty liver disease in part one of this two-episode series. Dr. Barritt is an Associate Professor of Medicine and the Director of Hepatology at the UNC Liver Center at the University of North Carolina.

Are you ready to take control of your health and transform your life? We're diving deep into the medical route to weight loss and discussing the amazing benefits of medications like semaglutide in reversing nonalcoholic fatty liver disease. Trust me, this is a game-changer! Dr. Joseph Moleski and Drew Shelton shared some eye-opening insights about the power of medical interventions in achieving sustainable weight loss and improving overall health. One of the key takeaways was the importance of protecting our liver by making smart dietary choices. Say goodbye to excessive sugar consumption and processed foods, and say hello to whole, nutritious foods that nourish your body from the inside out. "Your health is your wealth." - Dr. Joseph Moleski What you will learn: Nonalcoholic fatty liver disease and its consequences Potential reversal of nonalcoholic fatty liver disease with semaglutide Benefits and accessibility of compounded medications Learn more about Drew Shelton by visiting: Instagram Learn more about Dr. Joe and STL Medical Weight Loss by visiting: Website Book an Appointment Facebook Instagram

Join Drs Carol Wysham and Silvio Inzucchi as they discuss how type 2 diabetes management has evolved over the years, and the most promising developments on the horizon. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982419). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Continuous Glucose Monitoring in Persons With Type 2 Diabetes Not Using Insulin https://pubmed.ncbi.nlm.nih.gov/34633261/ Macrovascular Complications of Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30961498/ Rate of Decline in Kidney Function and Known Age-of-Onset or Duration of Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34282181/ Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/26378978/ Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27299675/ Tirzepatide Prescribing Information https://uspl.lilly.com/mounjaro/mounjaro.html#pi Glycemic Targets: Standards of Care in Diabetes-2023 https://pubmed.ncbi.nlm.nih.gov/36507646/ 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/30879355/ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update https://pubmed.ncbi.nlm.nih.gov/35963508/ 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/30165516/ The Role of BNP Testing in Heart Failure https://pubmed.ncbi.nlm.nih.gov/17168346/ Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) Rationale and Design https://pubmed.ncbi.nlm.nih.gov/32916609/ A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL) https://clinicaltrials.gov/ct2/show/NCT03914326 GLP-1 Receptor Agonists and Kidney Protection https://pubmed.ncbi.nlm.nih.gov/31159279/ Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study https://pubmed.ncbi.nlm.nih.gov/31589290/ A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6) https://clinicaltrials.gov/ct2/show/NCT04537923 The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD https://pubmed.ncbi.nlm.nih.gov/34406410/ Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/19523535/ Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30090738/

Dr. Amy Goss is an Assistant Professor of Nutrition Sciences at University of Alabama at Birmingham! She is also a Register Dietitian, and an early career investigator with expertise in conducting randomized clinical trials to examine the effects of diet quality and macronutrient composition on risk factors of chronic metabolic diseases such as obesity, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes. The goal of her research is to identify effective, sustainable, and non-invasive dietary means of preventing and reversing disease with metabolic origins. Dr. Goss specializes in MRI and MRS techniques for the assessment of fat distribution and organ lipid content in adult and pediatric populations. She recently has conducted studies using a family-based, controlled feeding experimental design aimed at improving outcomes in children with NAFLD. Dr. Amy Goss was a presenter at Low Carb Denver 2023, and did an amazing job presenting her talk title “Pediatric Non-alcoholic Fatty Liver Disease”, which will be the focus of our chat today. I met Dr. Goss in-person at that amazing conference!Find Dr. Goss at-TW- @AmyMGossIG- @dr.amygoss http://dietfordiabetes.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

In this episode of the School of Doza podcast, Nurse Doza discusses how to lose weight when you are insulin resistant. He starts by emphasizing the commitment needed to make these changes and encourages listeners to sign up for the newsletter on MSWLounge.com for weekly content and advice. Nurse Doza then explains that insulin resistance is common and leads to inflammation, and provides specific changes that can help with weight loss.   TIMESTAMPS: 00:00 Start 02:25 Insulin resistance and weight gain. 04:21  Insulin Resistance and Diabetes. 08:02 Leptin Resistance and Weight Loss. 11:50 Brown fat and weight loss. 19:42 Insulin resistance and weight loss. 24:29 Activation of parasympathetic nervous system. 27:23 Insulin Resistance and Weight Loss. 31:57 Resveratrol supplement.     Increase your energy levels and support your metabolism with Mitochondriac! Get 10% off when you use code NURSEDOZA at checkout. Visit the link to learn more and start feeling your best today! https://www.mswnutrition.com/mitochondriac         REFERENCES: What being insulin resistant means: _inflammation   your body is reluctant to release anymore insulin___ (1) “Insulin resistance is identified as an impaired biologic response to insulin stimulation of target tissues, primarily the liver, muscle, and adipose tissue” (2)   “You do not have to be overweight to have insulin resistance” (1)    “The spectrum of disease associated with insulin resistance includes obesity, cardiovascular disease, nonalcoholic fatty liver disease, metabolic syndrome, and polycystic ovary syndrome(PCOS).” (2)    Ways to measure IR: “HOMA-IR, serum triglyceride, and triglyceride/HDL ratio.” (2)   **“Insulin resistance is thought to precede the development of T2DM by 10 to 15 years. “ (2)   “While no medications are FDA approved for the treatment of insulin resistance” (3)  “Lifestyle modification should be the primary focus for the treatment of insulin resistance.” (3)   References: https://www.cdc.gov/diabetes/basics/insulin-resistance.html (1)  https://www.ncbi.nlm.nih.gov/books/NBK507839/ (2) IR: https://www.ncbi.nlm.nih.gov/books/NBK507839/ (3)    Leptin: “Leptin resistance is defined by a reduced sensitivity or a failure in response of the brain to leptin, showing a decrease in the ability of leptin to suppress appetite or enhance energy expenditure, which causes an increased food intake and finally leads to overweight, obesity, cardiovascular diseases, and other metabolic disorders” (1)   “A minor increase in leptin concentration reduces the appetite and leads to a decrease in body weight;3 however, in obesity, despite increased leptin concentration, the efficacy of the anorexic effect of leptin is decreased,1,3 with leptin resistance developing due to a defect in intracellular signaling associated with the leptin receptor or decreases in leptin transport across the blood–brain barrier (BBB)” (2)   “participation of leptin in the development of cardiovascular and autoimmune diseases and cancer” (2)  References: leptin: https://pubmed.ncbi.nlm.nih.gov/30390289/ (1) Leptin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354688/ (2) IR: https://www.ncbi.nlm.nih.gov/books/NBK507839/ (3)   References: leptin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354688/ (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815269/ (2)  https://academic.oup.com/jcem/article/91/12/4753/2656230?login=false (3)  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848049/ (4)   References: https://www.diabetes.co.uk/insulin/insulin-sensitivity.html (1) https://www.ncbi.nlm.nih.gov/books/NBK507839/ (2)  Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action https://pubmed.ncbi.nlm.nih.gov/28704113/ (3)  Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371579/ (4) https://academic.oup.com/jcem/article/91/12/4753/2656230?login=false (5)   References: The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease https://academic.oup.com/jcem/article/91/12/4753/2656230?login=false (1) https://www.pnas.org/doi/10.1073/pnas.2007856117 (2)    “In people with diabetes and pre-diabetes, increasing levels of HbA1c and age may be main factors related to impaired parasympathetic function” (1)   “Depression has been associated with both increased insulin resistance and reduced heart rate variability (HRV), the latter being an indicator of low parasympathetic drive” (2)   References: https://www.nature.com/articles/s41598-022-22675-2 (1)  https://www.researchgate.net/publication/47383873_Lower_Parasympathetic_Drive_Insulin_Resistance_and_Depression (2)   

The paper “Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease” is a clarion call to action, but what exactly should clinicians do? This conversation From the Vault addresses that issue. Louise Campbell starts by stating that the World Health Organization should incorporate Fatty Liver disease into their diabetes initiative. Next, she leads the group into a discussion of the merits of transient elastography, which leads Ken Cusi and Stephen Harrison to discuss blood-based and imaging options clinicians can deploy when they lack access to a FibroScan or similar device. Finally, Roger asks the most important step stakeholders should take now, which provide an array of different actions.

This episode covers:What you can do to support your liver and prevent non-alcoholic fatty liver disease. A new study about Vitamin C and cancer risk. A chocolate treat I have almost daily.Links I mentioned during this episode:Join Revitalize: www.thelyonsshare.org/revitalize  Blood Sugar Masterclass: https://mailchi.mp/thelyonsshare/sosliveclassBlog Post on Non-Alcoholic Fatty Liver Disease: bit.ly/preventfattyliverVitamin C and Cancer Study: https://www.frontiersin.org/articles/10.3389/fnut.2021.812394/fullVitamin C Supplement: https://amzn.to/2WLvCLrVital Proteins Chocolate Collagen: https://amzn.to/3WTI0rDSports Research Chocolate Collagen: https://amzn.to/3YfCZdMAll About Collagen's Benefits: https://www.thelyonsshare.org/2018/02/28/top-7-benefits-collagen-protein/Milk Thistle: https://amzn.to/3V56n5XBerberine: https://amzn.to/3JyOMzUProbiotics Blog Post and Brand Recommendations: https://www.thelyonsshare.org/2021/01/24/probiotics-vs-prebiotics-whats-the-difference-and-do-i-need-to-take-both/How to take action after listening to this episode:Do one thing today to support your liver health. This can be drinking a big glass of water, adding an extra serving of leafy greens to your plate, or finally taking the plunge and getting a probiotic. Whatever it is for you, take one step to support your liver. Your body will thank you!

What's up, Butterflies? In this episode of The Weight Is Over I'm going to dive into the topic of Non-Alcoholic Fatty Liver Disease, when did we first learn about it, how long it's been going on, how exactly is it sabotaging your weight loss efforts and what you can do to turn it around... stay tuned!

Do you know when to use noninvasive tests to assess advanced fibrosis in nonalcoholic fatty liver disease (NAFLD)? Join our hepatology experts and find out. Credit available for this activity expires: 01/20/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/985088?ecd=bdc_podcast_libsyn_mscpedu

KSQD 1-18-2023: Third year of COVID-19 -- Comments on masks; Bacterial contamination on common surfaces from keyboards to checkout kiosks in stores; Cold air does decrease your nose's immune response; Lead health hazard from cast iron tubs; New Alzheimer's drug targets Tau protein; UV light air purifiers; Discussion of artificial sweeteners and benefits of lecithin for brain health; AREDS2 formula for macular degeneration; Nonalcoholic fatty liver disease

This special episode of Inside Scope shares key insights from the AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease. This episode is hosted by Dr. Jana Al Hashash, member of the AGA Clinical Practice Update Committee. She is joined by: -Dr. Heather Patton, NAFLD expert and past member of the AGA Clinical Practice Update Committee -Dr. Joseph K. Lim, past chair of the AGA Clinical Practice Update Committee and co-author of this CPU -Dr. Zobair M Younossi, co-author of this CPU To access the full expert review, visit www.gastro.org/CPU.

Thank you for joining us for another episode of the Low Carb MD Podcast. Dr. Laura Buchanan is board certified in Family Medicine and is on the board of the Society of Metabolic Health Practitioners. She graduated summa cum laude with a Bachelor of Science in Biomedical Sciences from the University of South Florida and was a valedictorian of her class at the University of Florida College of Medicine. She is on staff at Dr. Tro's Medical Weight Loss & Direct Primary Care. In this special episode Drs. Tro and Laura discuss relevant articles in metabolic health and go into great scientific detail criticizing and expounding them. In this conversation, Drs. Tro and Laura discuss the findings and methods of two articles… The Effect of Calorie Un-Restricted, Low-Carbohydrate, High-Fat Diet versus High-Carbohydrate, Low-Fat Diet on Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease (published in the medical journal, Annals of Internal Medicine) Timestamp: (00:02:25) Read it HERE! The Long-term Effects of a Novel Continuous Remote-Care Intervention Including Nutritional Ketosis for the Management of Type-2 Diabetes: A Two-Year, Non-Randomized Clinical Trial (from Virta Health, published in the medical journal, Frontiers in Endocrinology)Timestamp: (00:34:50) Read it HERE! For more information, please see the links below. Thank you for listening! Links: Dr. Laura Buchanan: Twitter The Society of Metabolic Health Practitioners Website Instagram Dr. Tro Kalayjian: Website Twitter Instagram Dr. Brian Lenzkes: Website Twitter  

A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, “Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD).” Nonalcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome and is rapidly becoming one of the major causes of hepatic cirrhosis and hepatocellular carcinoma (HCC), although some cases of HCC have developed in non-cirrhotic livers [1–8]. Although the percentage of patients with NAFLD who ultimately progress to fibrosis and later to HCC is relatively small, the number is significant because of the sheer number of patients who have NAFLD. Because there are no reliable biomarkers to predict the risk of HCC in patients with NAFLD, designing effective and cost-effective surveillance programs aimed at prevention and early detection of HCC is difficult, if not impossible. Therefore, there is an urgent need to identify such biomarkers and especially those that may appear at different stages of progression toward HCC. In the current study, researchers Mamoun Younes, Lin Zhang, Baharan Fekry, and Kristin Eckel-Mahan from George Washington University School of Medicine and Health Sciences and McGovern Medical School at the University of Texas Health Science Center (UTHealth) studied the expression of two hepatocyte nuclear factor 4 alpha (HNF4α) isoforms, p-STAT3. and c-Myc in 49 consecutive liver biopsies with nonalcoholic fatty liver disease (NAFLD) using immunohistochemistry. “The aim of this study was to determine the relationships between p-STAT3, c-Myc and P2-HNF4α expression in biopsies from livers with NAFLD as potential biomarkers of HCC risk.” All 49 biopsies (100%) were positive for nuclear expression of P1-HNF4α. Twenty-eight (57%) cases were positive for P2-HNF4α, 6 (12%) were positive for p-STAT3 and 5 (10%) were positive for c-Myc. All 6 (100%) p-STAT3-positive cases were also positive for P2-HNF4α (p = 0.03). p-STAT3-positive cases were more likely to be positive for c-Myc (67% vs. 2%, p = 0.0003). Four cases were positive for P2-HNF4α, p-STAT3 and c-Myc. p-STAT3 expression was associated with hypertension (p = 0.037). All c-Myc positive biopsies were from patients with obesity, diabetes and hypertension. Only c-Myc expression was associated with advanced fibrosis; three (60%) of the c-Myc positive cases were associated with advanced fibrosis in contrast to 7 (10%) of the 44 c-Myc negative cases (p = 0.011). “Based on these results, we hypothesize with the following sequence of events with progression of NAFLD: P2-HNF4α expression is followed by expression of p-STAT3 which in turn is followed by the expression of c-Myc. Additional larger studies are needed to confirm these findings.” DOI: https://doi.org/10.18632/oncotarget.28324 Correspondence to: Mamoun Younes - myounes@mfa.gwu.edu Video: https://www.youtube.com/watch?v=LVR29K6P5I4 Keywords: hepatocyte nuclear factor four alpha, steatohepatitis, immunohistochemistry, hepatocellular carcinoma, isoform To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter - https://twitter.com/Oncotarget Facebook - https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram - https://www.instagram.com/oncotargetjrnl/ LinkedIn - https://www.linkedin.com/company/oncotarget/ Pinterest - https://www.pinterest.com/oncotarget/ LabTube - https://www.labtube.tv/channel/MTY5OA SoundCloud - https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com

This is a re-posting of Episode 59 due to audio problems with the original posting. Fructose is sweeter than glucose and is often added to processed foods as a sweetener, commonly in the form of high-fructose corn syrup. Some studies suggest that fructose consumption may be associated with nonalcoholic fatty liver disease, and some new research, recently presented at ENDO, addresses this issue. Host Aaron Lohr talks with one of the authors of this research, Theodore Friedman, MD, PhD, chairman of internal medicine at Charles R. Drew University of Medicine & Science and professor of medicine at University of California, Los Angeles. Dr. Friedman and colleagues’ oral presentation at ENDO 2022 is titled, “Fructose Consumption in Nonalcoholic Fatty Liver Disease in U.S. Adult Population of NHANES 17-18” (NHANES being a national health and nutrition examination survey). For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast.

Fructose is sweeter than glucose and is often added to processed foods as a sweetener, commonly in the form of high-fructose corn syrup. Some studies suggest that fructose consumption may be associated with nonalcoholic fatty liver disease, and some new research, recently presented at ENDO, addresses this issue. Host Aaron Lohr talks with one of the authors of this research, Theodore Friedman, MD, PhD, chairman of internal medicine at Charles R. Drew University of Medicine & Science and professor of medicine at University of California, Los Angeles. Dr. Friedman and colleagues’ oral presentation at ENDO 2022 is titled, “Fructose Consumption in Nonalcoholic Fatty Liver Disease in U.S. Adult Population of NHANES 17-18” (NHANES being a national health and nutrition examination survey). For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

Fructose is sweeter than glucose and is often added to processed foods as a sweetener, commonly in the form of high-fructose corn syrup. Some studies suggest that fructose consumption may be associated with nonalcoholic fatty liver disease, and some new research, recently presented at ENDO, addresses this issue. Host Aaron Lohr talks with one of the authors of this research, Theodore Friedman, MD, PhD, chairman of internal medicine at Charles R. Drew University of Medicine & Science and professor of medicine at University of California, Los Angeles. Dr. Friedman and colleagues’ oral presentation at ENDO 2022 is titled, “Fructose Consumption in Nonalcoholic Fatty Liver Disease in U.S. Adult Population of NHANES 17-18” (NHANES being a national health and nutrition examination survey). For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

Fructose is sweeter than glucose and is often added to processed foods as a sweetener, commonly in the form of high-fructose corn syrup. Some studies suggest that fructose consumption may be associated with nonalcoholic fatty liver disease, and some new research, recently presented at ENDO, addresses this issue. Host Aaron Lohr talks with one of the authors of this research, Theodore Friedman, MD, PhD, chairman of internal medicine at Charles R. Drew University of Medicine & Science and professor of medicine at University of California, Los Angeles. Dr. Friedman and colleagues’ oral presentation at ENDO 2022 is titled, “Fructose Consumption in Nonalcoholic Fatty Liver Disease in U.S. Adult Population of NHANES 17-18” (NHANES being a national health and nutrition examination survey). For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast

In episode #115, Dr. Jill interviews Dr. Asia Muhammad about the Gut Liver Axis and how it relates to Non-Alcoholic Fatty Liver Disease. They discuss the epidemic proportions of NAFLD in the United States, as well as some of the contributing factors.

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States, affecting almost 10 percent of all children. Sometimes referred to as "fatty liver disease," it is actually a range of diseases that all begin when excess fat gets deposited in the liver, most significantly impacting our obese patients. In today's episode we are joined by guest Shikha Sundaram, MD to discuss the clinical presentation and treatment of NAFLD, including how primary care providers can provide critical support to families making significant lifestyle changes as part of their treatment. Dr. Sundaram is the Medical Director of the Pediatric Liver Transplant Program at Children's Hospital Colorado and is Associate Professor of Pediatrics, Gastroenterology, Hepatology and Nutrition at the University of Colorado School of Medicine.  

Nonalcoholic fatty liver disease (NAFLD) is a major public health problem that will only worsen in the future, as it is closely linked to the epidemics of obesity and type 2 diabetes mellitus. Given this link, endocrinologists and primary care physicians are in an ideal position to identify persons at risk to prevent the development of cirrhosis and comorbidities. Join endocrine expert Vin Tangpricha, M.D., Ph.D., as he interviews AACE Co-Chairs, guideline task force experts, Kenneth Cusi, MD, FACP, FACE, and Scott D. Isaacs, MD, FACP, FACE, about the newly released 2022 clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease, published in the May 2022 issue of Endocrine Practice (https://www.endocrinepractice.org/article/S1530-891X(22)00090-8/fulltext).

Welcome to Protecting Your Nest with Dr. Tony Hampton. Tia Reid is a Certified Dietary Manager, LCHF Nutrition Coach, and is a licensed SUGAR coach. Before she began her low-carb health journey, Tia had been diagnosed with Type 2 Diabetes, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease, Hypertension, and Adrenal Insufficiency. With help from the great Dr. Cywes, she has had an amazing and inspiring recovering. She has come off of twenty medications over the course of her journey! In this discussion, Dr. Tony and Tia talk about: (00:01:33) The definition of omni carnivore (00:06:29) The negative self-perception accompanying obesity and other difficulties (00:11:09) How Tia helps her clients achieve their goals and foster self-confidence; helping them understand their urges, habits, and thoughts surrounding food (00:16:39) How to recognize wether or not you are carb addicted (00:21:08) The diagnostic criteria for sugar/carb addiction (00:23:23) Intermittent fasting (00:26:46) The variety of medications (and their cost) that Tia was on before she discovered the low-carb/high-fat diet (00:33:22) Fruit, nuts, and meat quality on the low-carb diet (00:40:25) Organizations and resources for more info on metabolic health Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.    Links:   Tia Reid: Instagram Nutrition Network Facebook Page Low Carb USA LowCarb Lifestyle Healing Hub Linkedin SMHP Profile Bitten's Addiction Addiction Reset Community Refresh, Renew, and Reboot Support Group   Dr. Tony Hampton: Linktree Instagram Account LinkedIn Account Ritmos Negros Podcast

Welcome to Protecting Your Nest with Dr. Tony Hampton. Tia Reid is a Certified Dietary Manager, LCHF Nutrition Coach, and is a licensed SUGAR coach. Before she began her low-carb health journey, Tia had been diagnosed with Type 2 Diabetes, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease, Hypertension, and Adrenal Insufficiency. With help from the great Dr. Cywes, she has had an amazing and inspiring recovering. She has come off of twenty medications over the course of her journey! Tune in next week for part 2 of this conversation with Tia. In this discussion, Drs. Tony and Tia talk about: (00:07:10) How Tia's family has been an invaluable support in her success (00:12:25) The many medical conditions that Tia has overcome with the help of Dr. Cywes (00:18:34) Tia's dietary experiments before finding discovering the low carb lifestyle (00:23:02) Tia's diabetes story (00:33:28) Tia's sleep apnea story (00:40:34) Uric Acid, gout, and kidney stones (00:42:25) Tia's experience with Non Alcoholic Fatty Liver Disease (00:47:39) Tia's experience with gestational diabetes (00:51:45) Tia's experience with Adrenal Insufficiency (00:59:27) Carbohydrate Addiction Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.    Links:   Tia Reid: Instagram Nutrition Network Facebook Page Low Carb USA LowCarb Lifestyle Healing Hub Linkedin SMHP Profile   Dr. Tony Hampton: Linktree Instagram Account LinkedIn Account Ritmos Negros Podcast

This PedsCases podcast presents an approach to nonalcoholic fatty liver disease. It was created by Stephanie Rohnm a medical student at McMaster University, in collaboration with Dr. Mary Zachos, a pediatric gastroenterologist at McMaster University.

In our last episode, we introduced you to Allison. She was dealing with:  Allison was dealing with brain fog, fatigue, and joint pain. She felt much older than her chronological years. Labs showed that her B vitamins, iron, and thyroid were all fine but her symptoms persisted. We spoke with Jason Earle who is the founder and CEO of 1-800-Got-Mold and has appeared as an expert on The Dr. Oz Show, Good Morning America, and Extreme Home Makeover. In that episode, he gave us so much great information about mold and debunked a whole bunch of myths around mold, how to test for it, and how to get rid of it. If you haven't listened to that episode, I highly recommend that you go back and give it a listen.  In this episode, we dive into how to regain your health once you've cleared the mold out of your house and have reduced exposure.    Exposure to Mold Through Diet Many of the symptoms related to mold exposure revolve around inflammation. Despite having dealt with the environmental exposure to mycotoxins and mold in your home, you may still be exposed to them in your diet. Grains, sugar, processed foods, and peanut butter. Removing these from your diet is the next step in detoxing from mold exposure. Doing a no sugar, no grains diet will also help reduce the inflammation that mold exposure will have contributed to.   Purging Mycotoxins from Your Body There are several ways to rid the body of mycotoxins after extended exposure. One is to purge them through sweat (exercise and saunas are great for this). Another is to take glutathione which will stimulate the release of mycotoxins in the body. Urine tests can confirm that mycotoxins are being released. Mycotoxins can be detected in blood and urine. You want to see the mycotoxins in the urine because that proves they are being released.  Jason cautions against believing in any absolute - any singular way to treat mycotoxin exposure. He personally had a bad experience with Cholestyramine despite others having reported being successful in removing toxins (along with removing cholesterol and other fats from the body). You have to find the approach that will work for you but Jason says that lifestyle changes may be the hardest but, in his experience, they are the most effective.    Treat Your Liver Well One of the parts of the body impacted by exposure to microbial VOCs is the liver. Nonalcoholic fatty liver disease is on the rise with an estimated 30% of Americans affected by it. The American Liver Foundation reports that about 100 million Americans have Nonalcoholic Fatty Liver Disease and that NAFLD is the most common form of liver disease in children (having doubled in the past 20 years).  Jason believes this is due to increased exposure to VOC (not just microbial but also chemical VOCs caused by off gassing from plastics, petroleum-based products and other man made products).  To protect the liver's health, decrease or eliminate alcohol and sugar. Use air purifiers. Get outside and work up a sweat.    Don't Ignore Musty Smells Jason reminds us that a musty smell indicates the presence of microbial VOCs. And, as was discussed in the last episode, it's not just mycotoxins we need to be concerned about. If there is a musty smell, then there are microbial VOCs present. Breathing these in along with chemical VOCs (which may not be detectable by odor alone) can cause health issues. It can cause inflammation, impeded breathing (especially for asthmatics), brain fog, and other health concerns.    Top Tips for Reducing Mold and Mold Related Issues To keep things simple, Jason recommends these lifestyle choices: Ventilate spaces well Use an air purifier Keep spaces clean (don't let mold accumulate - wet areas can go moldy in 72 hours) Eat clean (avoid mold harboring foods like sugar, grains, peanut butter, and processed foods) Exercise (sweating helps eliminate toxins from the body) Don't count on a pill (or magic bullet) to do the entire job Don't ignore or dismiss musty smells   Check Your History Jason became interested in the impact of mold on human health from his own experience. He grew up in a moldy farm house and was exposed to a lot of other types of toxins. As a result, he had asthma and many other health issues. It wasn't until he learned about mold, and was able to detox his system that he discovered what it felt like to be healthy. Mold may have been a part of your history too, think back to the buildings and spaces where you spent your time. This is the exposure to other environmental toxins you may have been (or continue to be) exposed to. These could have caused chronic inflammation and could be the root cause of your health issues.    Are you Exposed to Mold? The first step to eliminating mold exposure is to check the environments you spend most of your time in. Jason's company has a mold testing kit that you can find using this link. You'll also find free resources there including an ebook that will help you feel even more informed and in control of your situation. It's important to check your information sources because there is a lot of misinformation out there in this vast and somewhat unregulated field.    Mystery Solved  In Allison's case, we first worked with a certified mold inspector to find what was really going on and then she hired a mold remediator (who was not associated with the inspector) to have things properly cleaned and remediated. She got air purifiers to improve her indoor air quality. From a nutrition perspective, we ran some tests and found that her mitochondria were not functioning well (super common with mold exposure cases - especially those with sensitivities). We decided on a bottom-to-top approach. We first supported her bowels to ensure she is eliminating regularly. We then supported drainage of the liver with bile acids with Advanced TUDCA by CellCore. Along with this, we used their Biotoxin Binder which is a water soluble binder and does not include any charcoal.  After this we supported her liver, kidney and lymphatic system with KL Support and LymphActiv and worked on the mitochondria with molecular hydrogen and Mitochondrial NRG from Designs for Health.   Happy Ending The results for Allison were fantastic. As we were finishing up the protocol, she reported that her joint pain was completely gone (she'd already forgotten how bad it had been only weeks before). Now that her home environment has been cleared and her body is back in balance, she's thrilled to be feeling better again.    Eliminating Health Mysteries For Allison's case we were able to find that missing piece of the health puzzle and help her regain her health. Could this be the missing clue for you or someone in your life?    Links: Thanks to my guest Jason Earle. You can connect with him, access the Got Mold Test Kit as well as the free ebook on his website: https://www.gotmold.com/mysteriessolved/ Suggested Products: Advanced TUDCA BioToxin Binder by CellCore KL Support LymphActiv  Molecular H2 Mitochondrial NRG   Related Podcast Episodes: Busting the Biggest Myths about Mold and Mycotoxins The Case of Hidden Mold w/ Dr. Tim Jackson The Case of the Dizzy, Tired, Confused Brain w/ Evan Brand The Case of Becoming a Health Self-Advocate with Misty Williams   Thanks for Listening If you like what you heard, please rate and review this podcast. Every piece of feedback not only helps me create better shows, it helps more people find this important information.   Never miss an episode -  Subscribe NOW to Health Mysteries Solved with host, Inna Topiler on Apple Podcasts, Spotify, Stitcher or Google Podcasts and remember to rate and review the show! Find out more at http://healthmysteriessolved.com   PLEASE NOTE All information, content, and material on this podcast is for informational purposes only and is not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Some of the links provided are affiliate links. This means we may make a very small amount of money should you choose to buy after clicking on them. This will in no way affect the price of the product but it helps us a tiny bit in covering our expenses. 

Drs. Karl and Spencer Nadolsky discuss screening for and treating nonalcoholic fatty liver disease (NAFLD). Learn: - What NAFLD is - Why you should be aware of it - The difference between nonalcoholic fatty liver and nonalcoholic steatohepatitis - What to do if you get it - What diets are best to treat or prevent it

With nonalcoholic fatty liver disease affecting nearly a third of the US population, Luma Melo, University of Pittsburgh, describes how mouse studies have shown that low-impact exercise can help reverse liver damage. Dr. Melo also shares with co-hosts Anne Chappelle and David Faulkner how research funding works in her native Brazil and the role of Brazilian women in toxicology. About the GuestLuma Melo, PhD, University of Pittsburgh, started her scientific career in her native Brazil, earning a master's degree in physics from the University of São Paulo, where she also served as an Associated Instructor. She then earned a master's degree in the philosophy of science and medicine and a PhD in environmental health from Indiana University in the United States.Dr. Melo's research focuses on liver disease (both alcoholic and nonalcoholic fatty liver disease) and exercise. She is exploring mode of action and genetic expression related to how exercise and environmental chemicals modulate the development of nonalcoholic fatty liver diseases, as well as liver fibrosis and the mechanisms and determinants of mortality of alcoholic liver disease through translational studies including human samples and experimental models of liver disease. She also has conducted research involving aerobic exercise and breast cancer and published a book on quantum physics for laypeople titled But After All … What Is Quantum Physics?Dr. Melo is currently a Postdoctoral Associate at the University of Pittsburgh Medical Center and an Adjunct Professor with Ball State University.

Episode 90 features Dr. Hannah Awai back for her second time to talk about women's health in honor of International Women's Month. Hannah is a woman who values passion, connection, growth and contribution.  Work life started early for Hannah by way of delivering newspaper and waiting tables as a teenager in Colorado.  After completing undergraduate and medical school at Brown University, she launched into the healthcare field. She completed training in Pediatric Gastroenterology, Hepatology and Nutrition.  She has provided clinical care in hospital, outpatient clinic, and urgent care settings.  She has also been part of clinical research studies spanning topics such as Non Alcoholic Fatty Liver Disease and advanced liver imaging.  Currently, Hannah is the Medical Director of a federally funded program that serves chronically ill children from low income families in California.  This role includes making medical eligibility decisions, working with the regional hospital systems and insurance companion to assure the program runs smoothly, and working on policy with the California Department of Health Care Services.  Hannah finds balance outside her career by enjoying fitness and travel.  She coaches classes at OrangeTheory Fitness and enjoys seeing members through workouts that challenge them physically and mentally.  She also teaches group fitness at various resorts throughout Mexico and the Caribbean.  One of her personal goals is to explore 3 countries every year. She especially enjoys warm locations near the ocean.  When not engaged in the things above, you can find her listening to Janet Jackson, dancing in the living room, laughing and enjoying chocolate and ice cream.  For more information about Dr. Awai follow her on IG @yellorose16 or email us directly at drsean@bemoretoday.com --- Send in a voice message: https://anchor.fm/bemoretoday/message Support this podcast: https://anchor.fm/bemoretoday/support